Page 20 - IMO-2-1

Innovative Medicines & Omics Incretin mimetics in diabetes management

5. Powers MA, Bardsley J, Cypress M, et al. Diabetes self- doi: 10.3390/biology9120473
management education and support in type 2 diabetes: 16. Kuhre RE, Deacon CF, Holst JJ, Petersen N. What is an
A joint position statement of the American diabetes L-cell and how do we study the secretory mechanisms of the
association, the American association of diabetes educators, L-cell? Front Endocrinol. 2021;12:694284.
and the academy of nutrition and dietetics. Clin Diabetes.
2016;34(2):70-80. doi: 10.3389/fendo.2021.694284
doi: 10.2337/diaclin.34.2.70 17. El K, Campbell JE. The role of GIP in α-cells and glucagon
secretion. Peptides. 2020;125:170213.
6. Lu Y, Wang W, Liu J, Xie M, Liu Q, Li S. Vascular
complications of diabetes: A narrative review. Medicine doi: 10.1016/j.peptides.2019.170213
(Baltimore). 2023;102(40):e35285. 18. Salvatore T, Nevola R, Pafundi PC, et al. Incretin hormones:
doi: 10.1097/MD.0000000000035285 The Link between glycemic index and cardiometabolic
diseases. Nutrients. 2019;11(8):1878.
7. Chandrasekaran P, Weiskirchen R. The role of obesity
in type 2 diabetes mellitus-an overview. Int J Mol Sci. doi: 10.3390/nu11081878
2024;25(3):1882. 19. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the
doi: 10.3390/ijms25031882 treatment of type 2 diabetes mellitus. Nat Rev Endocrinol.
2020;16(11):642-653.
8. Yashi K, Daley SF. Obesity and type 2 diabetes. In: StatPearls.
Treasure Island, FL: StatPearls Publishing; 2023. doi: 10.1038/s41574-020-0399-8
20. Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-
9. Vieira R, Souto SB, Sánchez-López E, et al. Sugar-
lowering drugs for type 2 diabetes mellitus and metabolic like peptide-1 receptor agonists in the treatment of type 2
diabetes. Ann Pediatr Endocrinol Metab. 2017;22(1):15-26.
syndrome-review of classical and new compounds: Part-I.
Pharmaceuticals (Basel). 2019;12(4):152. doi: 10.6065/apem.2017.22.1.15
doi: 10.3390/ph12040152 21. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1
receptor: Mechanisms and advances in therapy. Signal
10. Kumar A, Mazumder R, Rani A, Pandey P, Khurana N. Novel
approaches for the management of type 2 diabetes mellitus: Transduct Target Ther. 2024;9(1):234.
An update. Curr Diabetes Rev. 2024;20(4):e051023221768. doi: 10.1038/s41392-024-01931-z
doi: 10.2174/0115733998261903230921102620 22. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide
1 (GLP-1). Mol Metab. 2019;30:72-130.
11. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical
review of antidiabetic drugs: Implications for type 2 diabetes doi: 10.1016/j.molmet.2019.09.010
mellitus management. Front Endocrinol (Lausanne). 23. Collins L, Costello RA. Glucagon-like peptide-1 receptor
2017;8:6. agonists. In: StatPearls. Treasure Island, FL: StatPearls
doi: 10.3389/fendo.2017.00006 Publishing; 2024. Available from: https://www.ncbi.nlm.nih.
gov/books/NBK551568 [Last accessed on 2024 Aug 23].
12. Al Musaimi O. Exploring FDA-approved frontiers: Insights
into natural and engineered peptide analogues in the 24. Davies MJ, Aroda VR, Collins BS, et al. Management of
GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH realms. hyperglycemia in type 2 diabetes, 2022. A consensus report
Biomolecules. 2024;14(3):264. by the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD).
doi: 10.3390/biom14030264 Diabetes Care. 2022;45:2753-2786.
13. Nauck MA, Müller TD. Incretin hormones and type 2 doi:10.2337/dci22-0034
diabetes. Diabetologia. 2023;66(10):1780-1795.
25. Latif W, Lambrinos KJ, Patel P, et al. Compare and contrast
doi: 10.1007/s00125-023-05956-x the glucagon-like peptide-1 receptor agonists (GLP1RAs).
14. Jinnouchi H, Sugiyama S, Yoshida A, et al. Liraglutide, In: StatPearls. Treasure Island, FL: StatPearls Publishing;
a glucagon-like peptide-1 analog, increased insulin 2024. Available from: https://www.ncbi.nlm.nih.gov/books/
sensitivity assessed by hyperinsulinemic-euglycemic clamp NBK572151 [Last accessed on 2024 Aug 23].
examination in patients with uncontrolled type 2 diabetes 26. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor
mellitus. J Diabetes Res. 2015;2015:706416. agonists in the treatment of type 2 diabetes-state-of-the-art.
doi: 10.1155/2015/706416 Mol Metab. 2021;46:101102.
15. Boer GA, Holst JJ. Incretin hormones and type 2 diabetes- doi: 10.1016/j.molmet.2020.101102
mechanistic insights and therapeutic approaches. Biology 27. American Diabetes Association. 9. Pharmacologic
(Basel). 2020;9(12):473. approaches to glycemic treatment: Standards of medical care

Volume 2 Issue 1 (2025) 14 doi: 10.36922/imo.4911